

REC REF	IRAS	Name of Trial	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready to Start	Reasons for delay correspond to:
16/EM/0193	190690	THE dal-GenE Trial: A phase 3 double blind randomised placebo controlled study to evaluate the effects of Dalcetrapib on cardiovascular risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)	04/11/2016	22/04/2016	06/10/2016	14/06/2016	29/09/2016	06/10/2016	Site Confirmed	03/11/2016	
16/NW/0787	216022	Albatross: A phase 2a randomised double blind placebo controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (Class III) mutation	10/03/2017	30/09/2016	06/01/2017	22/12/2016	16/02/2017	15/02/2017	Site Confirmed	16/02/2017	
16/WM/0436	208631	Archigen/AGB002-SAIT101 vs Rituximab in patients with low tumour burden FL		30/09/2016	04/01/2017	03/01/2017	23/03/2017	28/03/2017	Site Confirmed	04/04/2017	Neither
16/LO/1795	215435	GEKO 2: Intermittent Pneumatic Compression fo the foot versus Geko TM plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer patients: comparison of effects of lower limb circulation		13/01/2017	24/02/2017	23/11/2016	17/03/2017	15/03/2017	Site Confirmed		Sponsor
16/NW/0717	202204	PIROUETTE: A randomised double blind placebo controlled phase 2 study of the efficacy and safety of Pirfenidone in patients with Heart Failure and Preserved Left Ventricular Ejection Fraction	23/03/2017	22/11/2016	20/02/2017	15/12/2016	02/03/2017	02/03/2017	Site Confirmed	07/03/2017	
16/NE/0238	204031	Senior Rita: The British Heart Foundation older patients with non-ST segment Elevation Myocardial Infarction randomised interventional treatment trial		28/09/2016	07/02/2017	08/08/2016	21/02/2017	03/03/2017	Site Confirmed	15/03/2017	Neither
17/EM/0044	217658	Nintedanib: A double blind randomised placebo controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibroing Interstitial Lung Disease (PF-ILD)	12/06/2017	09/01/2017	24/04/2017	24/04/2017	15/05/2017	16/05/2017	Site Confirmed	26/05/2017	
17/NE/0115	218417	Multicentre, International, Double-blind, Two-arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients with Unclassifiable Progressive Fibrosing ILD.	15/08/2017	18/10/2016	22/06/2017	26/05/2017	29/06/2017	03/07/2017	Site Confirmed	05/07/2017	
16/EE/0305	190307	PrimeTime:	25/09/2017	02/02/2017	23/05/2017	03/11/2016	01/08/2017	10/08/2017	Site Confirmed	25/09/2017	Neither
16/WM/0118	182909	SMART: Sentimag along with routine evaluation of Sentinel Node Biopsy	11/09/2017	20/02/2017	10/03/2017	05/07/2016	17/07/2017	04/08/2017	Site Confirmed	14/08/2017	Sponsor
17/NI/0255	227279	A double-blind, randomized, placebo controlled study of the efficacy and safety of three doses of orvepitant in subjects with chronic refractory cough. (Volcano II)		06/03/2017	22/09/2017	26/07/2017	05/09/2017	15/09/2017	Site Confirmed	05/10/2017	
17/SC/0236	226436	Peanut Allergy oral immunotherapy study of AR101 for desensitisation in children and adults (Palisade) follow on study (ARC004)	21/08/2017	09/06/2017	15/08/2017	08/06/2017	10/08/2017	14/08/2017	Site Confirmed	17/08/2017	

16/WM/0472	211270	Confirm: Checkpoint blockade for Inhibition of Relapsed Mesothelioma: A phase 3 double-blind, placebo controlled trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma	29/06/2017	21/03/2017	23/04/2017	14/03/2017	07/06/2017	05/06/2017	Site Confirmed	12/06/2017	Sponsor
17/NI/0096	225743	HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS	06/09/2017	24/07/2017	23/08/2017	14/08/2017	23/08/2017	24/08/2017	Site Confirmed	31/08/2017	
17/SC/0016	218645	BMS CA209-743		17/03/2017	16/08/2017	16/03/2017	18/09/2017	22/09/2017	Site Confirmed		
16/NW/0629	211995	CF START		31/05/2017	24/08/2017	22/09/2016			Site Confirmed		
16/SS/0153	211403	CMR GUIDE		06/01/2017	11/08/2017	25/11/2016	19/07/2017	24/07/2017	Site Confirmed	11/08/2017	
17/EM/0060	215678	I1F-MC-RHBY ?COAST extension		25/11/2016	06/06/2017	25/04/2017			Site Confirmed		Sponsor
16/SC/0655	212212	Knee Replacement Bandaging Study (KREBS)		04/05/2017	04/09/2017	08/02/2017	06/09/2017	11/10/2017	Site Confirmed	12/10/2017	
16/SC/0462	208830	DRAFFT 2 - Distal Radius Acute Fracture Fixation Trial 2	04/09/2017	17/05/2017	14/07/2017	11/11/2016	03/08/2017	17/08/2017	Site Confirmed	18/08/2017	
16/NW/0718	204299	Clinical and cost effectiveness of the Respiratory Distress Symptom Intervention	13/07/2017	23/08/2016	16/06/2017	19/12/2016	09/06/2017	05/07/2017	Site Confirmed	05/07/2017	
17/NW/0019	212375	A3921192 SOAR ? A Study of a Once-A-day investigational drug for RA	28/07/2017	08/07/2016	28/04/2017	06/04/2017	02/06/2017	20/07/2017	Site Confirmed	20/07/2017	Sponsor
16/WM/0448	212745	Shire Solstice		19/06/2017	11/07/2017	08/02/2017	23/05/2017	05/06/2017	Site Confirmed	12/07/2017	Sponsor
17/LO/0794	223700	SPIRIT H2H		04/01/2017	28/07/2017	28/07/2017	24/09/2017	16/08/2017	Site Confirmed	25/09/2017	
16/SC/0109	163094	UK Study of tendo Achilles Rehabilitation ? multicentre randomised clinical trial		29/06/2017	18/09/2017	25/07/2016	29/09/2017	02/10/2017	Site Confirmed	03/10/2017	
17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	42984	24/07/2017	23/08/2017	14/08/2017	23/08/2017	24/08/2017	Site Confirmed	31/08/2017	
14/SC/1161	155743	e-Ultimaster	43004	29/03/2017	30/08/2017	19/08/2016	30/08/2016	20/09/2017	Site Confirmed	20/09/2017	

